open access

Vol 23, No 1 (2020)
Reviews
Published online: 2020-01-31
Submitted: 2019-12-18
Accepted: 2020-01-08
Get Citation

Radiolabelled PSMA PET/CT in breast cancer. A systematic review

Francesco Bertagna, Domenico Albano, Elisabetta Cerudelli, Maria Gazzilli, Davide Tomasini, Marco Bonù, Raffaele Giubbini, Giorgio Treglia
DOI: 10.5603/NMR.2020.0004
·
Pubmed: 32779172
·
Nucl. Med. Rev 2020;23(1):32-35.

open access

Vol 23, No 1 (2020)
Reviews
Published online: 2020-01-31
Submitted: 2019-12-18
Accepted: 2020-01-08

Abstract

BACKGROUND: Radiolabelled prostate-specific membrane antigen (PSMA)-based PET/CT is a whole-body imaging technique currently performed for the detection of prostate cancer lesions. PSMA has been also demonstrated to be expressed by the neovasculature of many other solid tumours. The aim of this review is to evaluate the possible diagnostic role of radiolabelled PSMA PET/CT in breast cancer.

MATERIAL AND METHODS: A comprehensive literature search of the PubMed/MEDLINE, Scopus, Embase and Cochrane Library databases was conducted to find relevant published articles about the diagnostic performance of radiolabelled PSMA PET/CT in breast cancer.

RESULTS: The comprehensive computer literature search revealed 652 articles. On reviewing the titles and abstracts, 640 articles were excluded because the reported data were not within the field of interest of this review. Twelve articles were selected and retrieved in full-text version; no additional study was found when screening the references of these articles. In total, 12 articles were included in the systematic review.

CONCLUSIONS: Further studies enrolling a wider population are needed to clarify the

Abstract

BACKGROUND: Radiolabelled prostate-specific membrane antigen (PSMA)-based PET/CT is a whole-body imaging technique currently performed for the detection of prostate cancer lesions. PSMA has been also demonstrated to be expressed by the neovasculature of many other solid tumours. The aim of this review is to evaluate the possible diagnostic role of radiolabelled PSMA PET/CT in breast cancer.

MATERIAL AND METHODS: A comprehensive literature search of the PubMed/MEDLINE, Scopus, Embase and Cochrane Library databases was conducted to find relevant published articles about the diagnostic performance of radiolabelled PSMA PET/CT in breast cancer.

RESULTS: The comprehensive computer literature search revealed 652 articles. On reviewing the titles and abstracts, 640 articles were excluded because the reported data were not within the field of interest of this review. Twelve articles were selected and retrieved in full-text version; no additional study was found when screening the references of these articles. In total, 12 articles were included in the systematic review.

CONCLUSIONS: Further studies enrolling a wider population are needed to clarify the

Get Citation

Keywords

PSMA; prostate specific membrane antibodies; breast cancer; PET; positron emission tomography

About this article
Title

Radiolabelled PSMA PET/CT in breast cancer. A systematic review

Journal

Nuclear Medicine Review

Issue

Vol 23, No 1 (2020)

Pages

32-35

Published online

2020-01-31

DOI

10.5603/NMR.2020.0004

Pubmed

32779172

Bibliographic record

Nucl. Med. Rev 2020;23(1):32-35.

Keywords

PSMA
prostate specific membrane antibodies
breast cancer
PET
positron emission tomography

Authors

Francesco Bertagna
Domenico Albano
Elisabetta Cerudelli
Maria Gazzilli
Davide Tomasini
Marco Bonù
Raffaele Giubbini
Giorgio Treglia

References (29)
  1. Treglia G, Annunziata S, Pizzuto DA, et al. Detection Rate of F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis. Cancers (Basel). 2019; 11(5).
  2. Wu H, Xu T, Wang X, et al. Diagnostic Performance of ⁶⁸Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis. World J Mens Health. 2019 [Epub ahead of print].
  3. Perera M, Papa N, Roberts M, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol. 2019 [Epub ahead of print].
  4. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015; 42(2): 197–209.
  5. Kratochwil C, Giesel FL, Eder M, et al. [¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015; 42(6): 987–988.
  6. Chang SS, Reuter VE, Heston WD, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999; 59(13): 3192–3198.
  7. Haffner MC, Kronberger IE, Ross JS, et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol. 2009; 40(12): 1754–1761.
  8. Kinoshita Y, Kuratsukuri K, Landas S, et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg. 2006; 30(4): 628–636.
  9. Hofman MS, Hicks RJ, Maurer T, et al. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics. 2018; 38(1): 200–217.
  10. Verburg FA, Krohn T, Heinzel A, et al. First evidence of PSMA expression in differentiated thyroid cancer using [⁶⁸Ga]PSMA-HBED-CC PET/CT. Eur J Nucl Med Mol Imaging. 2015; 42(10): 1622–1623.
  11. Taywade SK, Damle NA, Bal C. PSMA Expression in Papillary Thyroid Carcinoma: Opening a New Horizon in Management of Thyroid Cancer? Clin Nucl Med. 2016; 41(5): e263–e265.
  12. Noss KR, Wolfe SA, Grimes SR. Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. Gene. 2002; 285(1-2): 247–256.
  13. Bourgeois S, Gykiere P, Goethals L, et al. Aspecific Uptake of 68GA-PSMA in Paget Disease of the Bone. Clin Nucl Med. 2016; 41(11): 877–878.
  14. Bertagna F, Albano D, Giovanella L, et al. Ga-PSMA PET thyroid incidentalomas. Hormones (Athens). 2019; 18(2): 145–149.
  15. Polverari G, Ceci F, Calderoni L, et al. Male Breast Cancer Detected by Ga-PSMA-11 PET/CT in a Patient With Prostate Cancer With Pelvic Lymph Node Metastasis. Clin Genitourin Cancer. 2019; 17(2): 154–156.
  16. Daglioz Gorur G, Hekimsoy T, Isgoren S. Re: False Positive Uptake in Bilateral Gynecomastia on 68Ga-PSMA PET/CT Scan. Clin Nucl Med. 2018; 43(10): 785.
  17. Kumar R, Mittal BR, Bhattacharya A, et al. Synchronous Detection of Male Breast Cancer and Prostatic Cancer in a Patient With Suspected Prostatic Carcinoma on 68Ga-PSMA PET/CT Imaging. Clin Nucl Med. 2018; 43(6): 431–432.
  18. Malik D, Kumar R, Mittal BR, et al. 68Ga-Labeled PSMA Uptake in Nonprostatic Malignancies: Has the Time Come to Remove "PS" From PSMA? Clin Nucl Med. 2018; 43(7): 529–532.
  19. Medina-Ornelas SS, García-Pérez FO, Medel-Gamez C, et al. A single brain metastasis seen on Ga-PSMA PET/CT in recurrent breast cancer. Rev Esp Med Nucl Imagen Mol. 2018; 37(1): 61–62.
  20. Parihar AS, Mittal BR, Sood A, et al. 68Ga-Prostate-Specific Membrane Antigen PET/CT and 18F-FDG PET/CT of Primary Signet Ring Cell Breast Adenocarcinoma. Clin Nucl Med. 2018; 43(11): e414–e416.
  21. Passah A, Arora S, Damle NA, et al. 68Ga-Prostate-Specific Membrane Antigen PET/CT in Triple-Negative Breast Cancer. Clin Nucl Med. 2018; 43(6): 460–461.
  22. Tolkach Y, Gevensleben H, Bundschuh R, et al. Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy. Breast Cancer Res Treat. 2018; 169(3): 447–455.
  23. Sasikumar A, Joy A, Nair BP, et al. False Positive Uptake in Bilateral Gynecomastia on 68Ga-PSMA PET/CT Scan. Clin Nucl Med. 2017; 42(9): e412–e414.
  24. Sathekge M, Lengana T, Modiselle M, et al. Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. Eur J Nucl Med Mol Imaging. 2017; 44(4): 689–694.
  25. Malik D, Basher RK, Mittal BR, et al. 68Ga-PSMA Expression in Pseudoangiomatous Stromal Hyperplasia of the Breast. Clin Nucl Med. 2017; 42(1): 58–60.
  26. Sathekge M, Modiselle M, Vorster M, et al. ⁶⁸Ga-PSMA imaging of metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2015; 42(9): 1482–1483.
  27. Uría JA, Velasco G, Santamaría I, et al. Prostate-specific membrane antigen in breast carcinoma. Lancet. 1997; 349(9065): 1601.
  28. Salas Fragomeni RA, Amir T, Sheikhbahaei S, et al. Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. J Nucl Med. 2018; 59(6): 871–877.
  29. Wernicke AG, Varma S, Greenwood EA, et al. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. APMIS. 2014; 122(6): 482–489.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl